These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 9456256)

  • 21. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
    Younossi ZM; Nader FH; Bai C; Sjogren R; Ong JP; Collantes R; Sjogren M; Farmer D; Ramsey L; Terra K; Gujral H; Gurung C; Srishord M; Fang Y
    J Viral Hepat; 2008 May; 15(5):370-8. PubMed ID: 18194172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
    Vose JM; Crump M; Lazarus H; Emmanouilides C; Schenkein D; Moore J; Frankel S; Flinn I; Lovelace W; Hackett J; Liang BC
    J Clin Oncol; 2003 Feb; 21(3):514-9. PubMed ID: 12560443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial.
    Maher DW; Lieschke GJ; Green M; Bishop J; Stuart-Harris R; Wolf M; Sheridan WP; Kefford RF; Cebon J; Olver I; McKendrick J; Toner G; Bradstock K; Lieschke M; Cruickshank S; Tomita DK; Hoffman EW; Fox RM; Morstyn G
    Ann Intern Med; 1994 Oct; 121(7):492-501. PubMed ID: 7520676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of two different rG-CSF preparations in the treatment of patients with severe congenital neutropenia.
    Carlsson G; Ahlin A; Dahllöf G; Elinder G; Henter JI; Palmblad J
    Br J Haematol; 2004 Jul; 126(1):127-32. PubMed ID: 15198743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Filgrastim: new indication. AIDS-associated neutropenia: another soft indication.
    Prescrire Int; 2001 Aug; 10(54):106-7. PubMed ID: 11718177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: a multicenter, randomized, crossover phase 3 study.
    Shi YK; Chen Q; Zhu YZ; He XH; Wang HQ; Jiang ZF; Chang JH; Liu YP; Wang AL; Luo DY; Zhang Y; Ke XY; Li WL; Zhang WJ; Wang XW; Zhang YP; Wang JM; Liu XQ
    Anticancer Drugs; 2013 Jul; 24(6):641-7. PubMed ID: 23571496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegfilgrastim to accelerate neutrophil engraftment following peripheral blood stem cell transplant and reduce the duration of neutropenia, hospitalization, and use of intravenous antibiotics: a phase II study in multiple myeloma and lymphoma and comparison with filgrastim-treated matched controls.
    Wannesson L; Luthi F; Zucca E; Rosselet-Christ A; Baglioni M; Marelli L; Ghielmini M; Ketterer N
    Leuk Lymphoma; 2011 Mar; 52(3):436-43. PubMed ID: 21323524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human granulocyte colony-stimulating factor may improve outcome attributable to neonatal sepsis complicated by neutropenia.
    Kocherlakota P; La Gamma EF
    Pediatrics; 1997 Jul; 100(1):E6. PubMed ID: 9200380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.
    Gatzemeier U; Ciuleanu T; Dediu M; Ganea-Motan E; Lubenau H; Del Giglio A
    J Thorac Oncol; 2009 Jun; 4(6):736-40. PubMed ID: 19404210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin.
    Meza LA; Green MD; Hackett JR; Neumann TA; Holmes FA
    Pharmacotherapy; 2003 Nov; 23(11):1424-31. PubMed ID: 14620389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma.
    Sparano JA; Wiernik PH; Hu X; Sarta C; Schwartz EL; Soeiro R; Henry DH; Mason B; Ratech H; Dutcher JP
    J Clin Oncol; 1996 Nov; 14(11):3026-35. PubMed ID: 8918501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group.
    Yoshida M; Karasawa M; Naruse T; Fukuda M; Hirashima K; Oh H; Ninomiya H; Abe T; Saito K; Shishido H; Moriyama Y; Shibata A; Motoyoshi K; Nagata N; Miura Y
    Int J Hematol; 1999 Feb; 69(2):81-8. PubMed ID: 10071455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.
    Dale DC; Bonilla MA; Davis MW; Nakanishi AM; Hammond WP; Kurtzberg J; Wang W; Jakubowski A; Winton E; Lalezari P
    Blood; 1993 May; 81(10):2496-502. PubMed ID: 8490166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of HIV-related neutropenia.
    Wong RJ
    Am J Health Syst Pharm; 1999 Dec; 56 Suppl 5():S17-20. PubMed ID: 10613382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
    Lane SW; Crawford J; Kenealy M; Cull G; Seymour JF; Prince HM; Marlton P; Gill D; Mollee PN
    Leuk Lymphoma; 2006 Sep; 47(9):1813-7. PubMed ID: 17064993
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
    Stahel RA; Jost LM; Cerny T; Pichert G; Honegger H; Tobler A; Jacky E; Fey M; Platzer E
    J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
    García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L
    J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. The Filgrastim Study Group.
    Heard SO; Fink MP; Gamelli RL; Solomkin JS; Joshi M; Trask AL; Fabian TC; Hudson LD; Gerold KB; Logan ED
    Crit Care Med; 1998 Apr; 26(4):748-54. PubMed ID: 9559614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression.
    Beveridge RA; Miller JA; Kales AN; Binder RA; Robert NJ; Harvey JH; Windsor K; Gore I; Cantrell J; Thompson KA; Taylor WR; Barnes HM; Schiff SA; Shields JA; Cambareri RJ; Butler TP; Meister RJ; Feigert JM; Norgard MJ; Moraes MA; Helvie WW; Patton GA; Mundy LJ; Henry D; Sheridan MJ
    Cancer Invest; 1998; 16(6):366-73. PubMed ID: 9679526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Filgrastim and antibiotics treatment reduces neutropenia severity in solid cancer patients.
    Hassan BA; Yusoff ZB; Othman SB
    Asian Pac J Cancer Prev; 2009; 10(4):641-4. PubMed ID: 19827886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.